Polycythemia Vera (PV): Update on Emerging Treatment Options

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm causing excessive red blood cell production.
• PV significantly impacts patient quality of life and survival due to complications like thrombosis and transformation to advanced disease.
• Risk-adapted classification stratifies patients for tailored treatment approaches.

Purpose of the Study:

• To review current therapeutic strategies for Polycythemia Vera.
• To highlight the role of existing treatments like hydroxyurea and interferon.
• To discuss emerging therapies, including ruxolitinib and givinostat, for PV management.

Main Methods:

• Review of current clinical guidelines and therapeutic recommendations for Polycythemia Vera.
• Analysis of the efficacy and safety profiles of established and novel treatment agents.
• Examination of treatment strategies based on patient risk stratification (age, thrombotic history).

Main Results:

• Low-risk PV patients are managed with aspirin and phlebotomy.
• High-risk patients receive cytoreductive therapy, with hydroxyurea as the first-line choice.
• Ruxolitinib shows efficacy in specific patient subgroups, and givinostat demonstrates encouraging results in ongoing investigations.

Conclusions:

• Treatment decisions for PV are guided by risk stratification.
• Hydroxyurea remains a standard first-line cytoreductive therapy.
• Emerging agents like givinostat offer potential advancements in PV treatment, particularly for refractory cases.